Abstract
The pharmacokinetics of the antipsychotic agent risperidone were investigated in healthy young and elderly subjects, cirrhotic patients and patients with moderate and severe renal insufficiency. In a comparative trial, a single oral 1-mg dose was administered to fasting subjects. Plasma and urine concentrations of the parent compound risperidone and the active moiety (i.e. risperidone plus 9-hydroxy-risperidone) were measured by radioimmunoassays. No or only small changes in plasma protein binding were observed in hepatic and renal disease, whereas the protein binding was not influenced by aging. The inter-individual variability in plasma concentrations of the active moiety was much less than the variability in plasma concentrations of risperidone. Three out of six subjects, behaving like poor metabolizers, were on medication (thiethylperazine, amitriptyline, metoprolol) that may inhibit risperidone metabolism by CYP2D6 (debrisoquine 4-hydroxylase). The pharmacokinetics of risperidone in elderly and cirrhotic patients were comparable to those in young subjects, whereas total oral clearance was reduced in renal disease patients. The elimination rate and clearance of 9-hydroxy-risperidone was reduced in elderly and renal disease patients because of a diminished creatinine clearance. The CLoral of the active moiety, which is primarily 9-hydroxy-risperidone, was reduced by about 30% in the elderly and by about 50% in renal disease patients. In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients). Based upon the pharmacokinetics of the active moiety, a dose reduction and a cautious dose titration is advised in the elderly and in patients with renal disease. In cirrhotic patients, the single-dose pharmacokinetics were comparable to those in healthy young subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Affrime M, Reidenberg MM (1975) The protein binding of some drugs in plasma from patients with alcoholic liver disease. Eur J Clin Pharmacol 8:267–309
Andreasen F (1973) Protein binding of drugs in plasma from patients with acute renal failure. Acta Pharmacol Toxicol 32:417–429
Barre J, Houin G, Rosenbaum J, Zini R, Dhumaux D, Tillement J-P (1984) Decreased alpha-1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding. Br J Clin Pharmacol 18:652–653
Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36:537–547
Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S (1992) Risperidone versus haloperidol in the treatment of chronic schizofrenic inpatients: a multicentre double-blind comparative study. Acta Psychiat Scand 85:295–305
Docci D, Bilancioni R, Pistocchi E, Mosconi G, Turci F, Salvi G, Baldrati L, Orsi C (1985) Serum alpha-1-acid glycoprotein in chronic renal failure. Nephron 39:160–163
Dykbar R, Lauritzen M, Krauer R (1981) Relative reference values for clinical chemical and haematological quantities in “healthy” elderly people. Acta Med Scand 209:1–2
Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 46:377–394
Gelders YG, Heylen S, Vanden Bussche G, Reyntijens A, Janssen P (1990) Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23:206–211
Giles HG, Corrigall WA, Khouw V, Sellers EM (1982) Plasma protein binding of phencyclidine. Clin Pharmacol Ther 31:77–82
Greenblatt DY, Sellers EM, Shader RI (1982) Drug disposition in old age. N Engl J Med 306:1081–1088
Greenblatt DJ, Aberenthy DR, Shader RI (1986) Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit 8:249–255
Grossman SH, Davis D, Kitchell BB, Shand DG, Routledge PA (1982) Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 31:350–357
Hooper WD, Bochner F, Eadi MJ, Tyrer JH (1974) Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 15:276–282
Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Janssen A, Zylic Z, Visscher H, Jonkman J (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257–268
Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693
Kremer JMH, Wilting J, Janssen LHM (1988) Drug binding to alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1–47
Larsson M, Jagenburg R, Landahl S (1986) Renal function in an elderly population. A study ofS-creatinine,51Cr-EDTA clearance, endogenous creatinine clearance and maximal tubular water reabsorption. Scand J Clin Lab Invest 46:593–598
Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661–670
Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J (1993) Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 21:1134–1141
Mannens G, Meuldermanns W, Snoeck E, Heykants J (1994) Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology 114:566–572
McLennan WJ, Martin P, Mason BY (1977) Protein intake and serum albumin levels in elderlies. Gerontology 23:360–367
Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y (1989) Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 99:445–449
Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, Le Jeune L, Lauwers W, Heykants J (1993) The metabolism and excretion of risperdone after oral administration in rats and dogs. Drug Metab Dispos 22:129–138
Pacifici GM, Viani A, Taddeucci-Brunelli G, Rizzo G, Carrai M, Schulz HU (1986) Effects of development, aging and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and α1-acid glycoprotein: implictions for binding of drugs. Ther Drug Monit 8:259–293
Piafski KM, Borgå O, Odar-Cederlöf I, Johansson C, Sjöqvist F (1978) Increased plasma protein binding of propanolol and chlorpromazine mediated by disease-induced elevations of plasma alpha-1-acid glycoprotein. New Engl J Med 299:1435–1439
Reidenberg MM, Odar-Cederlöf I, von Bahr C, Borgå O, Sjöquist F (1971) Protein binding of diphenylhydantion and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 285:264–267
Reidenberg MM, Drayer DE (1984) Alternation of drug-protein binding in renal disease. Clin Pharacokinet 9 [Suppl 1]:18–26
Ritchell WA (1988) Gerontokinetics. The Telford Press, New Jersey
Ritchell WA (1992) Drug disposition in the elderly: gerontokinetics. Methods Find Exp Clin Pharmacol 14:555–572
Serbource-Goguel S, Durant G, Corbic M, Agneray J, Feger J (1986) Alternations in relative proportions of microheterogenous forms of human alpha-1-acid glycoprotein in liver disease. J Hepatol 2:245–252
Spina E, Martines C, Caputi AP, Cobaleda J, Piñas B, Carrillo JA, Benitez J (1991) Debrisoquin oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 41:467–470
Steiner E, Iselius L, Alvan G, Lindsten J, Sjöyvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394–401
Urien S, Albengres E, Tillement J.-P (1981) Serum protein binding of valproid acid in healthy subjects and in patients with liver disease. Int J Clin Pharmacol Ther Toxicol 19:319–325
van Beijsterveldt L, Geerts R, Leysen J, Megens A, Van den Eynde H, Meuldermans W, Heykants J (1993) The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 114:53–62
Verbeeck RK, Cardinal JA, Wallace SM (1984) Effects of age and sex on the plasma protein binding of acidic and basic drugs. Eur J Clin Pharmacol 27:91–104
Vestal RE (1989) Aging and determinants of hepatic drug clearance. Hepatology 9:331–334
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Snoeck, E., Van Peer, A., Mannens, G. et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 122, 223–229 (1995). https://doi.org/10.1007/BF02246543
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246543